Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 9/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.55 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.54 |
| ▸ | NR4A3 | Q92570 | 2/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.52 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30523116 | 1.00 | NR4A2 (0.65) | NR4A2KMT2AAKR1C3NPC1RAB9A | |
| SCHEMBL1572959 | 0.86 | KMT2A (0.71) | NR4A2KMT2AAKR1C3NPC1RAB9A | |
| SCHEMBL28029093 | 0.85 | PARP1 (0.62) | NR4A2KMT2A | |
| SCHEMBL30167982 | 0.85 | KMT2A (0.80) | NR4A2KMT2AAKR1C3NPC1RAB9A | |
| SCHEMBL9803295 | 0.85 | KMT2A (0.80) | NR4A2KMT2AAKR1C3NPC1RAB9A | |
| SCHEMBL10787479 | 0.85 | KMT2A (0.80) | NR4A2KMT2AAKR1C3NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL25378558 | 0.84 | KMT2A (0.69) | NR4A2KMT2AAKR1C3NR1H4 | |
| SCHEMBL14384059 | 0.84 | KMT2A (0.69) | NR4A2KMT2AAKR1C3NR1H4 | |
| SCHEMBL14384068 | 0.84 | KMT2A (0.69) | NR4A2KMT2AAKR1C3NR1H4 | |
| SCHEMBL4509654 | 0.83 | KMT2A (0.77) | NR4A2KMT2AAKR1C3NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011615-B2 | Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| EP-2945632-B1 | HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS SUITABLE FOR TREATMENT OR PREVENTION OF CENTRAL NERVOUS SYSTEM DISORDERS | MERCK SHARP & DOHME (US) | 2018-03-07 | — | — | EP | disclosed |
| US-9708347-B2 | Heterobicyclo-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170197991-A1 | HETEROBICYCLO-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20150361098-A1 | HETEROBICYCLO-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2015-12-17 | — | — | US | disclosed |
| EP-2945632-A1 | HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | Merck Sharp & Dohme Corp. (US) | 2015-11-25 | — | — | EP | disclosed |
| WO-2014105666-A1 | HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2014-07-03 | — | — | WO | disclosed |
| WO-2014101120-A1 | HETEROBICYCLO-SUBSTITUTED-7-METHOXY-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2014-07-03 | — | — | WO | disclosed |
| WO-2014101373-A1 | HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDER | MERCK SHARP & DOHME CORP. (US) | 2014-07-03 | — | — | WO | disclosed |
| CN-102076214-A | Gastrin releasing peptide compounds | BRACCO IMAGING SPA | 2011-05-25 | — | — | CN | disclosed |
| US-20100255934-A1 | COMPOSITIONS FOR GOLF EQUIPMENT | ACUSHNET COMPANY | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361098-A1 | HETEROBICYCLO-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | ADORA2A, ADORA3, ADORA1 | NR4A2 314/4885KMT2A 3700/4885AKR1C3 1525/4885 |
| US-20170197991-A1 | HETEROBICYCLO-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | ADORA2A, ADORA3, ADORA1 | NR4A2 301/4885KMT2A 3657/4885AKR1C3 1369/4885 |
| US-10011615-B2 | Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties | ADORA2A, ADORA3, ADORA1 | NR4A2 302/4885KMT2A 3810/4885AKR1C3 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.